Clarity Pharmaceuticals Ltd (ASX: CU6) shares were on fire on Monday.
The ASX 300 biotech stock rocketed 25% to end the day at $3.57.
But if you thought you might be late to the party, think again. That’s because Bell Potter believes the company may have just delivered what it calls “a breakthrough moment” and is tipping major upside for its shares from current levels.
Let’s see what the broker is saying.
‘A breakthrough moment’
Bell Potter’s note has been looking at the ASX 300 stock’s new abstract data, which was presented ahead of an upcoming conference presentation. The broker said:
The abstract of Professor Louise Emmett’s upcoming presentation of Co-PSMA data was released over the weekend. The study compared the detection rate per patient between 64Cu-SAR-bisPSMA and 68Ga-PSMA11 in men with biochemical recurrence (BCR) of prostate cancer [..] The aim of the study was to prove that 64Cu-SAR-bisPSMA is a superior agent for the detection of BCR of prostate cancer in men with low PSA levels.
The results were compelling. Bell Potter highlights:
64Cu-SAR-bisPSMA positively identified lesions in 39 of 50 patients (78%), compared to 18 of 50 patients (36%) with 68Ga-PSMA-11 [..] The investigators concluded that 64Cu-SAR-bis-PSMA PET CT identified a statistically higher number of disease recurrences compared to 68Ga-PSMA 11 with a high true positive rate (p <0.0001).
What happens next?
Attention now turns to the AMPLIFY Phase 3 approval study, which is currently recruiting 220 patients. Bell Potter adds:
The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA (AMPLIFY)⦠A similar true positive rate in the approval study is likely to warrant a highly differentiated label claim to currently marketed products for the detection of BCR, particularly in patients with low PSA levels.
Importantly, the broker also points out that supply of 64Cu is secured under long-term arrangements for the US market and that Clarity is well funded, with cash in excess of $226 million at the end of December.
Big potential returns for this ASX 300 stock
In response to the news, the broker has retained its speculative buy rating and $6.40 price target on the ASX 300 stock.
Based on its current share price of $3.57, this implies potential upside of almost 80% for investors over the next 12 months.
However, it is worth highlighting that its speculative rating means this would only be suitable for investors with a high tolerance for risk.
The post Why this ASX 300 stock could be a buy after ‘a breakthrough moment’ appeared first on The Motley Fool Australia.
Should you invest $1,000 in Clarity Pharmaceuticals right now?
Before you buy Clarity Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Clarity Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Guess which ASX 300 stock is jumping 18% on big news
- Argo Investments reports record profit and dividend
- Are these 2 ASX healthcare shares a buying opportunity after yesterday’s crash?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.